What's in Ethicon, Inc.'s pipeline?

Ethicon, Inc. has 9 drugs in our index: 4 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ethicon, Inc.'s portfolio?

Top competitors by shared drug class: Baxter Healthcare Corporation, Chang Gung Memorial Hospital, DeNova Research, Fundación para la Investigación del Hospital Clínico de Valencia, GATT Technologies BV.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ethicon-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Ethicon, Inc. — Portfolio Competitive Intelligence Brief

Ethicon, Inc. pipeline: 4 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
EVARREST® Fibrin Sealant Patch	EVARREST® Fibrin Sealant Patch	marketed
EVARREST™	EVARREST™	marketed	Topical hemostatic agent	Fibrinogen (Factor I) and thrombin (Factor IIa)	Surgery/Hemostasis
Bioseal Fibrin Sealant	Bioseal Fibrin Sealant	marketed	Fibrin sealant / Hemostatic agent		Surgery / Hemostasis
EVICEL Fibrin Sealant	EVICEL Fibrin Sealant	marketed
Fibrin Pad	Fibrin Pad	phase 3	Hemostatic agent		Surgery/Hemostasis
Topical hemostat	Topical hemostat	phase 3	Topical hemostat		Surgical
EVARREST™ Sealant Matrix	EVARREST™ Sealant Matrix	phase 3	Hemostatic sealant / Fibrin sealant		Surgery / Hemostasis
Fibrin Sealant 2 (FS2)	Fibrin Sealant 2 (FS2)	phase 3	Fibrin sealant / Hemostatic agent	Fibrinogen and thrombin (coagulation cascade)	Surgery / Hemostasis
Fibrin sealant (FS2)	Fibrin sealant (FS2)	phase 3	Hemostatic agent / Fibrin sealant		Surgery / Hemostasis

Therapeutic area mix

Surgery / Hemostasis · 4
Surgery/Hemostasis · 2
Surgical · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baxter Healthcare Corporation · 1 shared drug class
Chang Gung Memorial Hospital · 1 shared drug class
DeNova Research · 1 shared drug class
Fundación para la Investigación del Hospital Clínico de Valencia · 1 shared drug class
GATT Technologies BV · 1 shared drug class
Grifols Biologicals, LLC · 1 shared drug class
IBON JAUNARENA · 1 shared drug class
Ankara Ataturk Sanatorium Training and Research Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ethicon, Inc.:

Cite this brief

Drug Landscape (2026). Ethicon, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ethicon-inc. Accessed 2026-05-13.